Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

This review presents the early history, the motivation, the research and some of the backstories behind the discovery and development of sulfobutylether-β-cyclodextrin as a novel parenterally safe solubilizer and stabilizer. A specific sulfobutylether-β-cyclodextrin with an average degree of 6.5 sulfobutyl-groups variably substituted on the 2-, 3- and 6-hydroxyls of the seven glucopyranose (dextrose) units of β-cyclodextrin, is known by its commercial name, Captisol®. Today it is in 13 FDA approved injectables and numerous clinical candidates. It is also an example of a novel product discovered and initially preclinically developed at an academic institution. Copyright © 2020 Elsevier B.V. All rights reserved.

Citation

Valentino J Stella, Roger A Rajewski. Sulfobutylether-β-cyclodextrin. International journal of pharmaceutics. 2020 Jun 15;583:119396

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 32376442

View Full Text